Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

Stopped early · Phase 2

Conditions studied: Leukemia

In brief

RATIONALE: Imatinib mesylate and interferon alfa may interfere with the growth of the cancer cells. Combining imatinib mesylate with interferon alfa may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining imatinib mesylate with interferon alfa in treating patients who have chronic myelogenous leukemia.

Key facts

Study ID

NCT00015847

Run by

OHSU Knight Cancer Institute

People needed

25

Starts

2001-04-01

Expected to finish

2011-05-01

Last updated by the study team

2025-08-22

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Robert H. Lurie Comprehensive Cancer Center at Northwestern University — Chicago, Illinois, United States
• OHSU Knight Cancer Institute — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.